Context Therapeutics - FY23 focus squarely on CTIM-76
Context Therapeutics reported Q123 results and its strategic priority for FY23 and beyond. The key highlight for the quarter was its decision to...
204 Views
Context Therapeutics - R&D webinar highlights CTIM-76’s potential
Context Therapeutics’ April R&D webinar included takeaways from its poster presentation on CTIM-76 preclinical data at the AACR Annual Meeting...
284 Views
Context Therapeutics - Strategic pivot in pipeline focus
In an unexpected move, Context Therapeutics has announced that it will be discontinuing further development work on its ONA-XR program and...
405 Views
Context Therapeutics - Encouraging positive efficacy signals from OATH trial
Context Therapeutics has announced that two patients enrolled in the Phase II OATH trial (ONA-XR+anastrozole in advanced endometrial cancer) have...
238 Views
Context Therapeutics - Elacestrant approval shot in the arm for ELONA trial
On 27 January, the US FDA approved Stemline Therapeutics’ (wholly owned US subsidiary of the Menarini group) elacestrant (Orserdu) as second-line...
221 Views